β-blockers presented efficacy in migraine management by normalizing cortical network variability (CNV), reducing the dependence of evoked cortical potentials on the intensity of auditory stimuli, showing a high affinity for 5-hydroxytryptamine (5-HT) receptors 2B and 2C and inhibiting nitric oxide production by blocking inducible nitric oxide synthase (iNOS) (Siniatchkin et al., 2007; Sandor et al., 2000; Pradhan et al., 2018; Ramadan, 2004). Here, NOS2 is linked to migraine disorder.